Scienza e Tecnologia
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
In addition, the congress program features the following Telix initiatives:
Dr Colin Hayward , Telix Chief Medical Officer, said, "We are pleased to be so well represented at this year's EANM Annual Congress, with a sponsored symposium and abstracts accepted across Telix's late-stage prostate and kidney cancer imaging and therapy programs. In addition, our innovations in AI and quantum computing for prostate cancer segmentation and characterisation will be featured in an oral presentation.
"Once again, we will be supporting the EANM Sanjiv Sam Gambhir Young Investigator Award, an exciting opportunity for a junior physician or scientist to further develop their career in radiopharmaceuticals. We look forward to seeing you at booth number 241 to discuss Telix's industry leading theranostic pipeline and opportunities for collaboration."
Theranostics Track - Oncology & Theranostics Committee / EARL - Featured Session: Old but Novel Techniques
Zr-DFO-girentuximab PET/CT imaging for clear cell renal cell carcinoma - ZIRCON study results of diagnostic performance, including in very small lesions (oral presentation)
10-Sep-23, 4:20 - 4:30 PM
Clement Bailly , Nantes University Hospital, Nantes,
FRANCE
OP-194
Cutting Edge Science Track - TROP Session: Segmentation and Denoising
Using a 3-D UNet artificial intelligence model to segment PSMA-avid lesions in
Ga–PSMA–11 PET/CT images (top-rated oral presentation)
10-Sep-23, 4:55 – 5:05 PM
Simon Wail, Telix Pharmaceuticals,
North Melbourne, AUSTRALIA
OP-222
M2M Track - TROP Session: TME and Therapy: Direct Targeting and Secondary Effects
Evaluation of Therapeutic and Immunological Action of CAIX-Targeted Lutetium-177 Radionuclide Therapy Combined with Immune Checkpoint Inhibition (top-rated oral presentation)
11-Sep-23, 10:15 – 10:25 AM
Simone Kleinendorst , Department of Medical Imaging, Radboud University Medical Center, Nijmegen,
NETHERLANDS
OP-358
Clinical Oncology Track - TROP Session: Prostate Cancer Biochemical Recurrence
The imaging characteristics of theranostic Tc/ Re-PSMA-GCK01 is equivalent to dedicated diagnostic Tc-HYNIC-iPSMA in prostate cancer (top-rated oral presentation)
11-Sep-23, 6:05 – 6:15 PM
Eduards Mamlins, Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf,
Duesseldorf, GERMANY
OP-512
e-Poster Presentations Session 10 – Oncology & Theranostics Committee: Haematological and Abdominal Malignancies / localised Treatments
NOBLE (Nobody Left Behind) Registry: Initial Experience of [ Tc]-HYNIC-iPSMA Imaging in the Detection of Prostate Cancer (oral e-poster presentation)
12-Sep-23, 10:53 – 10:57 AM
Fuad Novruzov, Department of Nuclear Medicine Azerbaijan National Centre of Oncology,
Baku AZERBAIJAN
EPS-206
Cutting Edge Science Track - TROP Session: AI Methods and Applications
Primary prostate characterization in PSMA-11 PET on real quantum computers (top-rated oral presentation)
12-Sep-23, 3:00 – 03:10 PM
Laszlo Papp , Medical University of
Vienna , Vienna, AUSTRIA
OP-706
Clinical Oncology Track - TROP Session: Prostate Cancer Treatment
ProstACT GLOBAL: A Phase 3 Study of Lu-DOTA-rosopatamab (TLX591) With and Without the Best Standard of Care for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment with a Novel Androgen Axis Drug (top-rated oral presentation)
12-Sep-23, 3:30 – 3:40 PM
Neel Patel, Telix Pharmaceuticals,
North Melbourne, AUSTRALIA
OP-718
D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control
The Optimization of the Current ININ Method of Lu-177-DOTA-HYNIC-iPSMA (e-poster)
Yehia Omar, Misr Radiology Center,
Cairo, EGYPT
EP-0880
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn.
Telix's lead product, gallium-68 ( Ga) gozetotide (also known as Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. Telix is also progressing Marketing Authorisation Applications for Ga-PSMA-11 in the United Kingdom and the European Union.
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Legal Notices
Logo - https://mma.prnewswire.com/media/1920208/4254425/TeliMain_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telix-to-showcase-new-zircon-phase-iii-kidney-cancer-imaging-data-and-theranostic-pipeline-at-eanm-301918787.html